Abstract
MDC1 and 53BP1 are critical components of the DNA damage response (DDR) machinery that protects genome integrity and guards against cancer, yet the tissue expression patterns and involvement of these two DDR adaptors/mediators in human tumours remain largely unknown. Here we optimized immunohistochemical analyses of human 53BP1 and MDC1 proteins in situ and identified their virtually ubiquitous expression, both in proliferating and quiescent, differentiated tissues. Focus formation by 53BP1 and/or MDC1 in human spermatogenesis and subsets of breast and lung carcinomas indicated physiological and ‘pathological’ activation of the DDR, respectively. Furthermore, aberrant reduction or lack of either protein in significant proportions of carcinomas supported the candidacy of 53BP1 and MDC1 for tumour suppressors. Contrary to carcinomas, almost no activation or loss of MDC1 or 53BP1 were found among testicular germ-cell tumours (TGCTs), a tumour type with unique biology and exceptionally low incidence of p53 mutations. Such concomitant presence (in carcinomas) or absence (in TGCTs) of DDR activation and DDR aberrations supports the roles of MDC1 and 53BP1 within the ATM/ATR-regulated checkpoint network which, when activated, provides an early anti-cancer barrier the pressure of which selects for DDR defects such as p53 mutations or loss of 53BP1/MDC1 during cancer progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Albanell J, Bosl GJ, Reuter VE, Engelhardt M, Moore MA, Dmitrovsky E . (1999). Telomerase activity in germ cell cancers and mature teratomas. J Natl Cancer Inst 91: 1321–1326.
Bakkenist CJ, Kastan MB . (2004). Initiating cellular stress responses. Cell 118: 9–17.
Bartek J, Lukas J . (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3: 421–429.
Bartek J, Lukas J . (2007). DNA damage checkpoints: from initiation to recovery or adaptation. Current Opin Cell Biol 19: 1–8.
Bartek J, Lukas C, Lukas J . (2004). Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5: 792–804.
Bartek J, Mailand N . (2006). TOPping up ATR activity. Cell 124: 888–890.
Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, Skakkebæk NE, Sehested M, Lukas J et al. (2005a). ATM activation in normal human tissues and testicular cancer. Cell Cycle 4: 838–845.
Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. (2005b). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864–870.
Bartkova J, Rajpert-De Meyts E, Skakkebæk NE, Lukas J, Bartek J . (2003). Deregulation of the G1/S-phase control in human testicular germ cell tumours. APMIS 111: 252–265.
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. (2006). Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444: 633–637.
Bassing CH, Alt FW . (2004). The cellular response to general and programmed DNA double strand breaks. DNA Repair 3: 781–796.
Bekker-Jensen S, Lukas C, Melander F, Bartek J, Lukas J . (2005). Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are controlled by Mdc1/NFBD1. J Cell Biol 170: 201–211.
d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, von Zglinicki T et al. (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature 426: 194–198.
Di Micco R, Fumagalli M, Cicalese A, Piccini S, Gasparini P, Luise C et al. (2006). Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444: 638–642.
DiTullio RA, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J et al. (2002). 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 4: 998–1002.
Goldberg M, Stucki M, Falck J, D'Amours D, Rahman D, Pappin D et al. (2003). MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 421: 952–956.
Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T et al. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907–913.
Horejsi Z, Falck J, Bakkenist C, Kastan M, Lukas J, Bartek J . (2004). Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation. Oncogene 23: 3122–3127.
Huyen Y, Zgheib O, Ditullio Jr RA, Gorgoulis VG, Zacharatos P, Petty TJ et al. (2004). Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature 432: 406–411.
Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J et al. (2006). ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 8: 37–45.
Kastan M, Bartek J . (2004). Cell-cycle checkpoints and cancer. Nature 432: 316–323.
Kumagai A, Dunphy WG . (2000). Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. Mol Cell 6: 839–849.
Kumagai A, Lee J, Yoo HY, Dunphy WG . (2006). TopBP1 activates the ATR-ATRIP complex. Cell 124: 943–955.
Latella L, Lukas J, Simone C, Puri PL, Bartek J . (2004). Differentiation-induced radioresistance in muscle cells. Mol Cell Biol 24: 6350–6361.
Liu S, Bekker-Jensen S, Mailand N, Lukas C, Bartek J, Lukas J . (2006). Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation. Mol Cell Biol 26: 6056–6064.
Lou Z, Minter-Dykhouse K, Franco S, Gostissa M, Rivera MA, Celeste A et al. (2006). MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell 21: 187–200.
Lukas C, Bartkova J, Latella L, Falck J, Mailand N, Schroeder T et al. (2001). DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res 61: 4990–4993.
Lukas C, Melander F, Stucki M, Falck J, Bekker-Jensen S, Goldberg M et al. (2004a). Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention. EMBO J 23: 2674–2683.
Lukas J, Lukas C, Bartek J . (2004b). Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair 3: 997–1007.
Lutzker S, Levine AJ . (1996). A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Med 2: 804–810.
Mochan TA, Venere M, DiTullio RA, Halazonetis TD . (2003). 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res 63: 8586–8591.
Mochan TA, Venere M, DiTullio RA, Halazonetis TD . (2004). 53BP1, an activator of ATM in response to DNA damage. DNA Repair 3: 945–952.
Morales JC, Franco S, Murphy MM, Bassing CH, Millas KD, Adams MM et al. (2006). 53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis. Proc Natl Acad Sci USA 103: 3310–3315.
Nevanlinna H, Bartek J . (2006). The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25: 5912–5919.
Nowak R, Sikora K, Pietas A, Skoneczna I, Chrapusta SJ . (2000). Germ cell-like telomeric length homeostasis in nonseminomatous testicular germ cell tumors. Oncogene 19: 4075–4078.
Oosterhuis JW, Looijenga LHJ . (2005). Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 5: 210–222.
Petrini JH, Stracker TH . (2003). The cellular response to DNA double-strand breaks: defining the sensors and mediators. Trends Cell Biol 13: 458–462.
Pusapati RV, Rounbehler RJ, Hong S, Powers JT, Yan M, Kiguchi K et al. (2006). ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci USA 103: 1446–1451.
Rajpert-De Meyts E . (2006). Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Upd 12: 303–323.
Rajpert-De Meyts E, Bartkova J, Samson M, Hoei-Hansen CE, Frydelund-Larsen L, Bartek J et al. (2003). The emerging phenotype of the testicular carcinoma in situ germ cell. APMIS 111: 267–278.
Schultz LB, Chehab NH, Malikzay A, Halazonetis TD . (2000). p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol 151: 1381–1390.
Shiloh Y . (2003). ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3: 155–168.
Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ . (2003). MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421: 961–966.
Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP . (2005). MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123: 1213–1226.
Stucki M, Jackson SP . (2006). gammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair 5: 534–543.
Takai H, Smogorzewska A, de Lange T . (2003). DNA damage foci at dysfunctional telomeres. Curr Biol 13: 1549–1556.
Tort F, Bartkova J, Sehested M, Orntoft T, Lukas J, Bartek J . (2006). Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res 66: 10258–10263.
Ward IM, Difilippantonio S, Minn K, Mueller MD, Molina JR, Yu X et al. (2005). 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol 25: 10079–10086.
Ward IM, Minn K, van Deursen J, Chen J . (2003). p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol 23: 2556–2563.
Xu X, Stern DF . (2003). NFBD1/MDC1 regulates ionizing radiation-induced focus formation by DNA checkpoint signaling and repair factors. FASEB J 17: 1842–1848.
Acknowledgements
This work was supported by grants from the Danish Cancer Society, the Danish National Research Fund, the Danish Centre for Translational Breast Cancer Research, the European Commission (integrated projects ‘Active p53’, ‘DNA repair’ and ‘Mutant p53’), MSM (grant no. 6198959216) and Cancer Research UK.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Bartkova, J., Hořejs̆í, Z., Sehested, M. et al. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26, 7414–7422 (2007). https://doi.org/10.1038/sj.onc.1210553
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210553
Keywords
This article is cited by
-
Targeting MDC1 promotes apoptosis and sensitizes Imatinib resistance in CML cells by mainly disrupting non-homologous end-joining repair
Medical Oncology (2022)
-
MDC1 depletion promotes cisplatin induced cell death in cervical cancer cells
BMC Research Notes (2020)
-
NFBD1/MDC1 participates in the regulation of proliferation and apoptosis in human laryngeal squamous cell carcinoma
Clinical and Translational Oncology (2018)
-
TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas
Oncogene (2017)
-
Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours
Cellular Oncology (2017)